Targeted therapy using engineered antibodies for pancreatic cancer
Official title: Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer
Funded at Beckman Research Institute/city of Hope · NIH-11005732 · Data updated 2026-11-12
This study is testing a new type of treatment for advanced pancreatic cancer that uses specially designed antibodies to target a specific protein found in many pancreatic tumors, aiming to make the treatment more effective while protecting healthy organs from radiation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $600,896 |
| NIH project number | 5R01CA266665-04 |
| Project ID | NIH-11005732 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced pancreatic cancer who express the Prostate Stem Cell Antigen.
✕Less likely to help
Patients with pancreatic cancer who do not express the Prostate Stem Cell Antigen may not benefit from this targeted therapy.
What this research studies
This research focuses on developing engineered antibodies that target the Prostate Stem Cell Antigen (PSCA), which is found in a high percentage of pancreatic cancer cases. By utilizing a specialized antibody fragment designed for effective delivery of therapeutic radionuclides, the research aims to improve treatment outcomes for patients with advanced pancreatic cancer. The approach includes biodistribution studies in mouse models to confirm targeting and clearance, followed by efficacy testing in various pancreatic cancer models. This innovative method seeks to minimize radiation exposure to healthy organs while maximizing treatment effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with advanced pancreatic cancer.
How similar studies have gone: Previous research has shown promising results with targeted radionuclide therapies in other cancer types, indicating potential for success with this novel approach in pancreatic cancer.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Wu, Anna M — Beckman Research Institute/city of Hope
- Study coordinator: Wu, Anna M
Related research
Other NIH-funded projects on the same topics.
-
PSCA-targeted antibody for imaging and treating pancreatic cancer
A specially engineered antibody is used to find and deliver targeted radiation to pancreatic tumors that have high PSCA levels.
-
New imaging technique for pancreatic cancer treatment response
This study is testing a new imaging method to help doctors see pancreatic cancer better and understand how well different treatments might work for patients, so they can tailor the best care for each person.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.